Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Investor Presentation (September 2023)
21 slides from Invivyd's investor presentation, Sep 11, 2023
Slide 1: Corporate Overview September 2023
Exhibit 99.1 CORPORATE OVERVIEW September 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Invivyd is on a mission to rapidly deliver antibodies that protect vulnerable populations
INVIVYD IS ON A MISSION TO RAPIDLY DELIVER ANTIBODIES THAT PROTECT VULNERABLE POPULATIONS FROM VIRAL THREATS, STARTING WITH COVID-19 Near-Term Opportunity 8-18M Zero immunocompromised people authorized or approved EUA pathway provides the in the U.S. alone who may not monoclonal antibodies opportuni
Slide 4: Many immunocompromised people have an impaired response to vaccines
MANY IMMUNOCOMPROMISED PEOPLE HAVE AN IMPAIRED RESPONSE TO VACCINES AND LESS PROTECTION AGAINST SEVERE COVID-19 OUTCOMES Immunocompromised people are less likely to have detectable SARS- Immunocompromised people generate less protection against severe CoV-2 antibodies following vaccination than immu
Slide 5: COVID-19 vaccine effectiveness has waned even in immunocompetent populations
EVEN IN PRIMARILY IMMUNOCOMPETENT POPULATIONS, COVID-19 VACCINE EFFECTIVENESS (VE) HAS WANED Monovalent boosters provided 90% VE against symptomatic Bivalent boosters have shown 4-29% VE against infection with more recent Omicron variants Delta infection vs. 46% VE against symptomatic Omicron infect
Slide 6: Monoclonal antibodies have potential in prevention and treatment of COVID-19
IN ADDITION TO PREVENTION, MONOCLONAL ANTIBODIES ALSO HAVE COMPELLING POTENTIAL IN THE TREATMENT OF COVID-19 PREVENTION TREATMENT Vaccines mAbs Antivirals Anti-SARS-CoV-2 mAbs are expected to provide: • Rapid, passive immunity Limitations for the Limitations for the immunocompromised: • Utility for
Slide 7: Prevention of COVID-19 in vulnerable populations presents a long-term value proposition
PREVENTION OF COVID-19 IN VULNERABLE POPULATIONS PRESENTS A COMPELLING, POTENTIAL LONG-TERM VALUE PROPOSITION $2.2B in total revenue of Evusheld® in 2022, a mAb previously 1 authorized to protect vulnerable populations from COVID-19 $1,400 $1,270M $1,200 In a 2023 survey of U.S. physicians $1,000 $9
Slide 8: Summer uptick foreshadows potential fall and winter waves
SUMMER UPTICK FORESHADOWS POTENTIAL FALL AND WINTER WAVES AND HIGHLIGHTS ONGOING NEED FOR COVID-19 THERAPEUTICS More older adults have been hospitalized for Covid-19 over the past several weeks, according to data reviewed by health insurer Humana. August 28, 2023 September 6, 2023 August 17, 2023 Ju
Slide 9: HCPs report a significant subset of immunocompromised people at high risk
HCPs CONTINUE TO REPORT THAT A SIGNIFICANT SUBSET OF IMMUNOCOMPROMISED PEOPLE ARE AT HIGH-RISK OF SEVERE COVID-19 Risk of severe COVID -19 for select immunocompromised populations 1 according to July 2023 survey of specialty HCPs in the U.S. 1 = No greater risk compared to the general population; 10
Slide 10: Our Platform & VYD222
Our Platform & VYD222 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 11: Platform-based approach designed to keep pace with viral evolution
INVIVYD IS TAKING A PLATFORM-BASED APPROACH DESIGNED TO KEEP PACE WITH VIRAL EVOLUTION By leveraging state-of-the-art viral surveillance, antibody discovery and engineering, we aim to continuously discover and optimize mAb candidates that can perpetually protect the vulnerable from serious viral thr
Slide 12: VYD222: engineered for broad activity and prolonged utility
VYD222: ENGINEERED FOR BROAD ACTIVITY AND PROLONGED UTILITY Ph 2/3 clinical trial of ADG20 for COVID-19 prevention RBD Spike ACE2 Ph 2/3 clinical trial of ADG20 for COVID-19 treatment VYD222 Broadly neutralizing, half-life extended Binds to the spike protein receptor Engineered from adintrevimab mAb
Slide 13: VYD222 broad in vitro neutralizing activity against variants
VYD222 HAS DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST VARIOUS PRE-OMICRON AND OMICRON VARIANTS 1 VARIANT SUBLINEAGE VYD222 WT(D614G) WT(D614G) ✓ Delta B.1.617.2 ✓ BA.1 ✓ BA.4/5 ✓ BA.4.6 ✓ BF.7 ✓ Omicron XBB.1 ✓ XBB.1.5 ✓ XBB.1.5.10 and EG.5 (one of the XBB.1.16 ✓ dominant variants in
Slide 14: Rapidly advancing VYD222 for prevention of symptomatic COVID-19
INVIVYD IS RAPIDLY ADVANCING VYD222 FOR THE PREVENTION OF SYMPTOMATIC COVID-19 Dosed first Reported positive Dosed first participant participants in Phase 1 initial Phase 1 in Phase 3 pivotal clinical trial clinical data clinical trial (CANOPY) Q1 2023 Q2 2023 Q3 2023 Q4 2023 Anticipated initial pri
Slide 15: Positive initial VYD222 Phase 1 data show strong serum neutralizing titers
POSITIVE INITIAL VYD222 PHASE 1 CLINICAL TRIAL DATA SHOW STRONG SERUM NEUTRALIZING TITERS & FAVORABLE SAFETY PROFILE • 30 healthy volunteers enrolled across three different dosing cohorts; in each cohort, participants were randomized 8:2 to VYD222 or placebo • Initial clinical trial data showed that
Slide 16: CANOPY Phase 3 trial designed to rapidly generate clinical data for potential EUA
THE CANOPY PHASE 3 CLINICAL TRIAL OF VYD222 IS DESIGNED TO RAPIDLY GENERATE CLINICAL DATA FOR A POTENTIAL EUA VYD222 4500 mg IV (n=300) COHORT A Open Label Immunocompromised // (N=300) Day 1 Day 28 Month 3 Month 12 (Dosing) (Primary (Redosing) (Last visit) efficacy Primary endpoints: endpoint) • Saf
Slide 17: Serum neutralizing titers from immunocompromised cohort used in CANOPY primary analysis
DAY 28 SERUM NEUTRALIZING TITERS FROM IMMUNOCOMPROMISED COHORT WILL BE USED IN THE CANOPY PRIMARY EFFICACY ANALYSIS Serum neutralizing titers (either mAb or vaccine-induced) have been shown to correlate with protection against symptomatic COVID-19 The CANOPY clinical trial primary efficacy analysis
Slide 18: VYD222 is one of many antibodies in Invivyd's pipeline
VYD222 IS ONE OF MANY ANTIBODIES IN INVIVYD’S ROBUST PIPELINE DISCOVERY/ PROGRAMS PLATFORM INDICATION(S) IND-ENABLING PHASE 1 PHASE 2 PHASE 3 STATUS PRECLINICAL CORONAVIRUSES Initiated Ph 3 clinical trial VYD222 mAb Prevention in Sept 2023 COVID Prevention or Engineering variant mAb candidate #2 tre
Slide 19: Management team with expertise in infectious diseases
MANAGEMENT TEAM WITH EXPERTISE IN INFECTIOUS DISEASES AND TRACK RECORD OF SUCCESS Peter C. Schmidt, M.D., MSc Stacy Price, M.S. William Duke, M.B.A Dave Hering, M.B.A. Chief Medical Officer Chief Technology & Manufacturing Officer Chief Financial Officer Chief Executive Officer & Director Jill Ander
Slide 20: Poised to enter a transformational period
INVIVYD IS POISED TO ENTER A TRANSFORMATIONAL PERIOD, WITH A NEAR-TERM OPPORTUNITY TO DELIVER A MUCH NEEDED THERAPEUTIC Providing vulnerable populations, such as immunocompromised people, with protection from COVID-19 is a compelling, potential long-term value proposition Invivyd is rapidly executin
Slide 21: Thank You!
THANK YOU!